FoodAllergiesHub.com: Are parents buying Epipen carriers that could hurt...
FoodAllergiesHub.com: Are parents buying Epipen carriers that could hurt...: Finding and choosing an Epipen carrier that kids will be willing to use can be more than challenging. The WaistPal is by far the best for ki...
Who invented the new Auvi-Q epinephrine talking devise?
UPDATE: In late October 2015, Sanofi US recalls all Auvi-Q and Allerject devises. Will let you know as soon as they get back in the market. We hope to see them back soon.
Twin brothers Eric and Evan Edwards grew up with severe food allergies and having to self carry Epipen's at all times motivated them to create the Auvi-Q. rectangular devise. The Epipen and Auvi-Q contain the same drug epinephrine, which can help stop a severe allergic reaction, known as anaphylaxis from becoming fatal.
The brothers had the idea of creating a smaller and easier to carry epinephrine auto injector devise and they geared their studies in fields that would help them reach their goal. Evan chose engineering, studying at the University of Virginia. Eric pursued a medical path, eventually earning a doctorate in pharmaceutical sciences from Virginia Commonwealth University.
One of the courses Evan chose was an invention and design class taught by Larry G. Richards, an engineering professor at the University of Virginia, where students were encouraged to share their ideas with one another. Working with Mr. Richards and another professor he kept working on his idea of creating a rectangular devise and was awarded a college inventors grant that provided the initial start-up financing that help start the project. After college, the brothers founded a company, Intelliject, to bring their idea to market
with the investments from family and friends.
The brothers idea resulted in the invention of a slim device shaped like a smartphone with automated voice instructions that became available for consumers to buy in the US in January 2013.
The launch of Auvi-Q marked the culmination of an amazing quest the Edwards brothers began 15 years ago. Their efforts and hard work resulted in the creation, development, and distribution of an epinephrine auto injector devise that will help save the life of many who suffer from anaphylaxis allergies, and for which food allergic individuals and their families will always be grateful for.
 |
| Eric and Evan Edward at age 3 |
The brothers had the idea of creating a smaller and easier to carry epinephrine auto injector devise and they geared their studies in fields that would help them reach their goal. Evan chose engineering, studying at the University of Virginia. Eric pursued a medical path, eventually earning a doctorate in pharmaceutical sciences from Virginia Commonwealth University.
One of the courses Evan chose was an invention and design class taught by Larry G. Richards, an engineering professor at the University of Virginia, where students were encouraged to share their ideas with one another. Working with Mr. Richards and another professor he kept working on his idea of creating a rectangular devise and was awarded a college inventors grant that provided the initial start-up financing that help start the project. After college, the brothers founded a company, Intelliject, to bring their idea to market
with the investments from family and friends.
The product evolved as the years passed, retaining its rectangular
profile but integrating other innovative features along the way. Eric had the idea
of adding voice instructions to help others use the device in situations
where they might be too panicked to read written instructions. A
retractable needle was also added later, with the thought that patients
would be more comfortable if they didn’t have to see it.
 |
| Eric, left, and Evan Edwards |
In 2009, Intelliject licensed the product to Sanofi for
an initial payment of $25 million and up to $205 million in future
milestone payments and royalties. The Food and Drug Administration
approved the Auvi-Q in summer 2012.
The brothers idea resulted in the invention of a slim device shaped like a smartphone with automated voice instructions that became available for consumers to buy in the US in January 2013.
The launch of Auvi-Q marked the culmination of an amazing quest the Edwards brothers began 15 years ago. Their efforts and hard work resulted in the creation, development, and distribution of an epinephrine auto injector devise that will help save the life of many who suffer from anaphylaxis allergies, and for which food allergic individuals and their families will always be grateful for.
Auvi-Q epinephrine auto-injector talking devise now available in the US.
Sanofi announced today that Auvi-Q™ (epinephrine injection, USP) is
now available in U.S. retail pharmacies nationwide with a prescription
from a healthcare provider.
Auvi-Q is the first-and-only epinephrine auto-injector with audio and visual cues for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The size and shape of a credit card and the thickness of a smart phone, Auvi-Q is a breakthrough in epinephrine auto-injector device design that talks patients and caregivers step-by-step through the injection process.
"Patient feedback was a critical component to the development process for Auvi-Q," said Anne Whitaker, President, North America Pharmaceuticals, Sanofi. "The availability of Auvi-Q represents an important step forward in our continued innovation to meet the needs of people at risk for anaphylaxis and their caregivers."
Up
to six million Americans may be at risk for anaphylaxis, although the
precise incidence is unknown and likely under-reported. While guidelines
emphasize the importance of the life-saving role of epinephrine, two
large surveys
show that two-thirds of patients and caregivers do not carry their
epinephrine auto-injectors as recommended, and nearly half worry that
others will not know how to use their or their child's epinephrine
auto-injector correctly during an emergency.
Multiple studies have found an association between delay in epinephrine administration and death from anaphylaxis.
Life-threatening allergic reactions may occur as a result of exposure to allergens including foods such as peanuts, tree nuts, fish, shellfish, dairy, eggs, soy and wheat; insect stings; latex and medication, among other allergens and causes.
About Auvi-Q
Auvi-Q provides users with audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete. Auvi-Q also features an automatic retractable needle mechanism to help prevent accidental needle sticks.
Available in two different dosages, Auvi-Q 0.3mg delivers 0.3mg epinephrine injection and is intended for patients who weigh 66 pounds or more. Auvi-Q 0.15mg delivers 0.15mg epinephrine injection and is intended for patients who weigh 33 – 66 pounds. Auvi-Q has not been studied in patients weighing less than 33 pounds. Each Auvi-Q pack contains two devices - containing one dose of epinephrine each - and a non-active training device. Auvi-Q received U.S. Food and Drug Administration approval in August 2012.
Sanofi US licensed the North America commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world. Eric and Evan Edwards, twin brothers who suffer from life-threatening allergies, and co-founders of Intelliject, Inc., developed Auvi-Q with a team of world class engineers and scientists. The development process incorporated real-world experiences and feedback from patients and caregivers.
Auvi-Q has been named an International CES Innovations 2013 Design and Engineering Awards Honoree.
Indication
Auvi-Q (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions.
Important Safety Information
Auvi-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after use. Each Auvi-Q contains a single dose of epinephrine.
Auvi-Q should only be injected into your outer thigh. DO NOT INJECT INTO BUTTOCK OR INTRAVENOUSLY. If you accidentally inject Auvi-Q into any other part of your body, seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
If you take certain medicines, you may develop serious life-threatening side effects from epinephrine. Be sure to tell your doctor all the medicines you take, especially medicines for asthma. Side effects may be increased in patients with certain medical conditions, or who take certain medicines. These include asthma, allergies, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure, and heart disease.
The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These side effects go away quickly, especially if you rest.
Talk to your healthcare professional to see if Auvi-Q is right for you.
About Anaphylaxis
The signs and symptoms of anaphylaxis can vary from person to person and from one episode to the next. Some people may have hives/itching, facial or tongue swelling, which makes it difficult to breathe or swallow, while others may experience nausea and vomiting. These symptoms may begin within seconds, minutes or hours after exposure to the allergen. The best prevention method for anaphylaxis is avoidance of the specific allergen(s).
When a severe, life-threatening allergic reaction occurs, epinephrine should be administered immediately and patients and caregivers should seek immediate medical attention. Patients and caregivers should always carry and know how to use an epinephrine auto-injector to treat emergency allergic reactions. Without treatment, anaphylaxis can result in death within a matter of minutes.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit Sanofi or call 1-800-981-2491.
UPDATE: In late October 2015, Sanofi US recalls all Auvi-Q and Allerject devises. Will let you know as soon as they get back in the market. We hope to see them back soon
by: Marlena Delgado Coen
Auvi-Q is the first-and-only epinephrine auto-injector with audio and visual cues for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The size and shape of a credit card and the thickness of a smart phone, Auvi-Q is a breakthrough in epinephrine auto-injector device design that talks patients and caregivers step-by-step through the injection process.
"Patient feedback was a critical component to the development process for Auvi-Q," said Anne Whitaker, President, North America Pharmaceuticals, Sanofi. "The availability of Auvi-Q represents an important step forward in our continued innovation to meet the needs of people at risk for anaphylaxis and their caregivers."
Up
to six million Americans may be at risk for anaphylaxis, although the
precise incidence is unknown and likely under-reported. While guidelines
emphasize the importance of the life-saving role of epinephrine, two
large surveys
show that two-thirds of patients and caregivers do not carry their
epinephrine auto-injectors as recommended, and nearly half worry that
others will not know how to use their or their child's epinephrine
auto-injector correctly during an emergency.Multiple studies have found an association between delay in epinephrine administration and death from anaphylaxis.
Life-threatening allergic reactions may occur as a result of exposure to allergens including foods such as peanuts, tree nuts, fish, shellfish, dairy, eggs, soy and wheat; insect stings; latex and medication, among other allergens and causes.
About Auvi-Q
Auvi-Q provides users with audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete. Auvi-Q also features an automatic retractable needle mechanism to help prevent accidental needle sticks.
Available in two different dosages, Auvi-Q 0.3mg delivers 0.3mg epinephrine injection and is intended for patients who weigh 66 pounds or more. Auvi-Q 0.15mg delivers 0.15mg epinephrine injection and is intended for patients who weigh 33 – 66 pounds. Auvi-Q has not been studied in patients weighing less than 33 pounds. Each Auvi-Q pack contains two devices - containing one dose of epinephrine each - and a non-active training device. Auvi-Q received U.S. Food and Drug Administration approval in August 2012.
Sanofi US licensed the North America commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world. Eric and Evan Edwards, twin brothers who suffer from life-threatening allergies, and co-founders of Intelliject, Inc., developed Auvi-Q with a team of world class engineers and scientists. The development process incorporated real-world experiences and feedback from patients and caregivers.
Auvi-Q has been named an International CES Innovations 2013 Design and Engineering Awards Honoree.
Indication
Auvi-Q (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions.
Important Safety Information
Auvi-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after use. Each Auvi-Q contains a single dose of epinephrine.
Auvi-Q should only be injected into your outer thigh. DO NOT INJECT INTO BUTTOCK OR INTRAVENOUSLY. If you accidentally inject Auvi-Q into any other part of your body, seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
If you take certain medicines, you may develop serious life-threatening side effects from epinephrine. Be sure to tell your doctor all the medicines you take, especially medicines for asthma. Side effects may be increased in patients with certain medical conditions, or who take certain medicines. These include asthma, allergies, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure, and heart disease.
The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These side effects go away quickly, especially if you rest.
Talk to your healthcare professional to see if Auvi-Q is right for you.
About Anaphylaxis
The signs and symptoms of anaphylaxis can vary from person to person and from one episode to the next. Some people may have hives/itching, facial or tongue swelling, which makes it difficult to breathe or swallow, while others may experience nausea and vomiting. These symptoms may begin within seconds, minutes or hours after exposure to the allergen. The best prevention method for anaphylaxis is avoidance of the specific allergen(s).
When a severe, life-threatening allergic reaction occurs, epinephrine should be administered immediately and patients and caregivers should seek immediate medical attention. Patients and caregivers should always carry and know how to use an epinephrine auto-injector to treat emergency allergic reactions. Without treatment, anaphylaxis can result in death within a matter of minutes.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit Sanofi or call 1-800-981-2491.
UPDATE: In late October 2015, Sanofi US recalls all Auvi-Q and Allerject devises. Will let you know as soon as they get back in the market. We hope to see them back soon
by: Marlena Delgado Coen
Subscribe to:
Posts (Atom)